The U.S. Food and Drug Administration allowed Kitov Pharmaceuticals Holdings Ltd. to use the brand name Consensi for marketing its drug KIT-302.
The permission is subject to receipt of marketing approval from the regulator.
Consensi is a combination of two FDA-approved drugs — Pfizer Inc.'s Celebrex and Norvasc. It is intended to simultaneously treat pain caused by osteoarthritis, as well as hypertension, which is a common side effect of stand-alone drugs that treat osteoarthritis pain.
The expected completion date for FDA's review of the new drug application for Consensi is May 31, 2018.